Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 2
2006 2
2007 2
2009 6
2010 3
2011 1
2012 5
2013 4
2014 3
2015 3
2016 2
2017 7
2018 10
2019 7
2020 15
2021 25
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

87 results
Results by year
Filters applied: . Clear all
Page 1
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.
Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, Xu J, Wilke C, Gandhi KK, Socié G; REACH2 Trial Group. Zeiser R, et al. N Engl J Med. 2020 May 7;382(19):1800-1810. doi: 10.1056/NEJMoa1917635. Epub 2020 Apr 22. N Engl J Med. 2020. PMID: 32320566 Clinical Trial.
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F; REACH3 Investigators. Zeiser R, et al. N Engl J Med. 2021 Jul 15;385(3):228-238. doi: 10.1056/NEJMoa2033122. N Engl J Med. 2021. PMID: 34260836 Clinical Trial.
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D'Aveni-Piney M, Obéric L, Bodet-Milin C, Bories P, Olivier P, Lafon I, Berriolo-Riedinger A, Galli E, Bernard S, Rubio MT, Bossard C, Meignin V, Merlet P, Feugier P, Le Gouill S, Ysebaert L, Casasnovas O, Meignan M, Chevret S, Thieblemont C. Vercellino L, et al. Among authors: rubio mt. Blood Adv. 2020 Nov 24;4(22):5607-5615. doi: 10.1182/bloodadvances.2020003001. Blood Adv. 2020. PMID: 33180899 Free PMC article.
Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape.
Zalmaï L, Viailly PJ, Biichle S, Cheok M, Soret L, Angelot-Delettre F, Petrella T, Collonge-Rame MA, Seilles E, Geffroy S, Deconinck E, Daguindau E, Bouyer S, Dindinaud E, Baunin V, Le Garff-Tavernier M, Roos-Weil D, Wagner-Ballon O, Salaun V, Feuillard J, Brun S, Drenou B, Mayeur-Rousse C, Okamba P, Dorvaux V, Tichionni M, Rose J, Rubio MT, Jacob MC, Raggueneau V, Preudhomme C, Saas P, Ferrand C, Adotevi O, Roumier C, Jardin F, Garnache-Ottou F, Renosi F. Zalmaï L, et al. Among authors: rubio mt. Haematologica. 2021 Dec 1;106(12):3056-3066. doi: 10.3324/haematol.2020.253740. Haematologica. 2021. PMID: 33054115 Free PMC article.
Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Guillaume T, Malard F, Magro L, Labopin M, Tabrizi R, Borel C, Chevallier P, Vigouroux S, Peterlin P, Garnier A, Rubio MT, Huynh A, Milpied N, Moreau P, Gaugler B, Yakoub-Agha I, Mohty M. Guillaume T, et al. Among authors: rubio mt. Bone Marrow Transplant. 2019 Nov;54(11):1815-1826. doi: 10.1038/s41409-019-0536-y. Epub 2019 May 14. Bone Marrow Transplant. 2019. PMID: 31089280 Clinical Trial.
Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study.
Azoulay É, Castro P, Maamar A, Metaxa V, de Moraes AG, Voigt L, Wallet F, Klouche K, Picard M, Moreau AS, Van De Louw A, Seguin A, Mokart D, Chawla S, Leroy J, Böll B, Issa N, Levy B, Hemelaar P, Fernandez S, Munshi L, Bauer P, Schellongowski P, Joannidis M, Moreno-Gonzalez G, Galstian G, Darmon M, Valade S; Nine-I investigators. Azoulay É, et al. Lancet Haematol. 2021 May;8(5):e355-e364. doi: 10.1016/S2352-3026(21)00060-0. Lancet Haematol. 2021. PMID: 33894170 Free article.
[Awareness on the law of bioethics].
Bay JO, Dalle JH, Dulery R, Magro L, Nguyen-Quoc S, Robin M, Rubio MT, Huynh A. Bay JO, et al. Among authors: rubio mt. Bull Cancer. 2020 May;107(5):541-542. doi: 10.1016/j.bulcan.2020.04.005. Epub 2020 Apr 30. Bull Cancer. 2020. PMID: 32386707 French. No abstract available.
Biologie, concepts et principes des CAR-T cells.
Rubio MT, Galaine J, Borg C, Daguindau É. Rubio MT, et al. Bull Cancer. 2018 Dec;105 Suppl 2:S135-S146. doi: 10.1016/S0007-4551(19)30044-X. Bull Cancer. 2018. PMID: 30686352 French.
[Mechanisms of resistance and escape to CAR-T cells].
Grinda T, Brouard J, Tran D, Rubio MT. Grinda T, et al. Among authors: rubio mt. Bull Cancer. 2021 Oct;108(10S):S128-S140. doi: 10.1016/j.bulcan.2021.09.002. Bull Cancer. 2021. PMID: 34920795 Review. French.
87 results